CYCLOSPORINE IN DERMATOLOGY: PHARMACOLOGY AND CLINICAL USE

International Journal of Dermatology

Volumn 33, Issue 2, 1994, Pages 86-95

  KAUVAR, ARIELLE B ^a   STILLER, MATTHEW J ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANDROGEN; ANTIBIOTIC AGENT; AZATHIOPRINE; CALCIUM ANTAGONIST; CARBAMAZEPINE; CIMETIDINE; COLESTYRAMINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DANAZOL; DIGOXIN; DIURETIC AGENT; ERYTHROMYCIN; ETRETINATE; HYDROXYCHLOROQUINE; KETOCONAZOLE; MELPHALAN; METHOTREXATE; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PREDNISONE; TRIBUTYL PHOSPHOROTRITHIOITE; TRIMETHOPRIM; UNINDEXED DRUG;

BEHCET DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ORAL DRUG ADMINISTRATION; PSORIASIS; PYODERMA; REVIEW;

CYCLOSPORINE; HUMAN; SKIN DISEASES; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028295228     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4362.1994.tb01533.x     Document Type: Article

References (199)

1. Biologic effects of cyclosporine A: a new antilymphocytic agent
2. The effects of cyclosporine A on the immune system
3. Cyclosporine A — usefulness, risks, and mechanism of action
4. Cyclophillin: a specific cytosolic bonding protein for cyclosporine A
5. Peptidyl‐prolyl cistrans isomerase is the cyclosporine A‐binding protein cyclophilin
6. Cyclophilin and peptidyl‐prolyl cistrans isomerase are probably identical proteins
7. Mechanisms of action of cyclosporine: effect on cells of the immune system and on subcellular events in T cell activation
8. Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes
9. Cyclosporine: immunology, pharmacology and therapeutic uses
10. Pharmacokinetics and metabolism of cyclosporine A
11. Cyclosporine: pharmacokinetics, metabolism and drug interactions
12. Cyclosporine: pharmacokinetics and metabolism
13. The role of cytochromes P‐450 in cyclosporine metabolism
14. Cyclosporine A drug interactions: screening for inducers and inhibitors of cytochrome P450 (cyclosporine A oxidase) in primary cultures of human hepatocytes
15. Renal effects of cyclosporine
16. Laboratory monitoring of cyclosporine levels: guidelines for the dermatologist
17. Nephrotoxicity of cyclosporine A
18. Reversibility of cyclosporine nephrotoxicity after three months' treatment
19. Side effects of systemic cyclosporine in patients not undergoing trans plantation
20. Effect of cyclosporine administration on renal hemodynamics in conscious rats
21. Cyclosporine associated chronic neophropathy
22. Renal histopathologic alterations in patients treated with cyclosporine for uveitis
23. Morphologic renal changes during cyclosporine treatment of psoriasis
24. Renal function and biopsy findings after 5 years' treatment with low‐dose cyclosporine for psoriasis
25. Sustained renal function loss in psoriasis patients after withdrawal of low‐dose cyclosporine therapy
26. Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day
27. The effect of short‐term low dose cyclosporine on renal function and blood pressure in patients with psoriasis
28. Acutely impaired renal function during intravenous cyclosporine A: a cremaphore side effect
29. New onset of hypertension following cardiac transplantation: a preliminary report and analysis
30. Nephrotoxicity and hypertension in patients with autoimmune diseases treated with cyclosporine
31. Long term cyclosporine in the management of psoriasis
32. Cyclosporine maintenance therapy in psoriasis
33. Effects of cyclosporine therapy on plasma lipoprotein levels
34. Alterations in lipid and carbohydrate metabolism attributable to cyclosporine A in renal transplant recipients
35. Elevation of fasting serum lipids in patients treated with low‐dose cyclosporine for plaque‐type psoriasis
36. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
37. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients
38. Effect of cyclosporine on plasma lipids and modification with dietary fish oil
39. Management of patients and side effects during cyclosporine therapy for cutaneous disorders
40. Clinical and pharmacological correlations in cyclosporine‐induced gingival hyperplasia
41. Hypertrichosis in patients receiving cyclosporine therapy
42. Does cyclosporine A influence sex hormone levels
43. Development and incidence of cancer following cyclosporine therapy
44. Skin cancer in renal transplant patients treated with cyclosporine
45. Two distinct squamous cell carcinomas in a psoriasis patient receiving low‐dose cyclosporine maintenance treatment
46. Cutaneous lesions in 67 cyclosporine treated renal transplant recipients
47. Decreased peripheral blood eosinophil counts in severe psoriatic patients treated with low‐dose cyclosporine A
48. Assessment of the risks of malignancy and lymphomas developing in patients using Sandimmune
49. Lymphomas and lymphoproliferative lesions under cyclosporine therapy
50. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine‐steroid therapy
51. Effect of erythromycin on cyclosporine levels
52. Pharmacodynamics of cyclosporine‐ketoconazole interaction in mice
53. Time course of cyclosporine‐ketoconazole interaction in mice
54. Norfloxacin‐cyclosporine interaction
55. High dose methylprednisolone increases plasma cyclosporine levels in renal transplant recipients
56. Oral contraceptive interactions with cyclosporine
57. Toxicity of cyclosporine during treatment with androgens
58. Interaction of cyclosporine and calcium antagonists
59. Cyclosporine‐ cimetidine interaction
60. Cyclosporine interacting with danazol and norethisterone
61. Interaction between phenytoin and cyclosporine following organ transplantation
62. Interaction between cyclosporine A and phenobarbitone
63. Gyclosporine and tegretol — another drug interaction
64. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin
65. Cyclosporine and intravenous sulphadimidine and trimethoprim
66. Enhancement of cyclosporine nephrotoxicity by diuretic therapy
67. Cyclosporine treatment for rheumatoid arthritis: a place bocontrolled double blind multicentre study
68. Severe nephrotoxicity caused by the combined use of gentamicin and cyclosporine in renal allograft recipients
69. Nephrotoxicity of trimethoprim and cotrinioxazole in renal allograft recipients treated with cyclosporine
70. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation
71. Cyclosporine interaction with ketoconazole and melphalan
72. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
73. Digoxin‐cyclosporine interaction: severe digitalis toxicity after cyclosporine treatment
74. Cyclosporine for psoriasis
75. Cyclosporine for psoriasis
76. Cyclosporine for psoriasis
77. Cyclosporine A treatment for severe psoriasis
78. Clearance of psoriasis with low dose cyclosporine
79. Cyclosporine in the treatment of psoriasis
80. Short‐term use of cyclosporine A in severe psoriasis
81. Clearance of psoriasis with low dose cyclosporine
82. Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study
83. Treatment of resistant severe psoriasis with systemic cyclosporine
84. Treatment of severe psoriasis with low dose cyclosporine A and the effect on the helper‐suppressor T cell ratio in peripheral blood
85. Cyclosporine for plaque‐type psoriasis: results of a multidose, double‐blind trial
86. Cyclosporine in psoriasis: a multicenter dose‐finding study in severe plaque psoriasis
87. Consensus conference on cyclosporine A for psoriasis, February 1992
88. Therapeutic efficacy of oral low‐dose cyclosporine A in severe psoriatic arthritis
89. Cyclosporine improves psoriasis in a double‐blind study
90. Life‐threatening psoriasis relapse on withdrawal of cyclosporine
91. Cyclosporine versus etretinate: Italian multicenter comparative trial in severe plaque‐form psoriasis
92. Short and long‐term considerations concerning the management of plaque psoriasis with low‐dose cyclosporine
93. Cyclosporine therapy in psoriasis: recommendations for treatment
94. Guidelines for cure of psoriasis
95. Cutaneous lesions in 67 cyclosporine‐treated renal transplant recipients
96. Generalized pustular psoriasis responding to cyclosporine A
97. Cyclosporine A in acrodermatitis continua
98. Intralesional injection of cyclosporine in psoriasis
99. Intralesional cyclosporine in the treatment of psoriasis
100. Topical cyclosporine A in the treatment of psoriasis
101. Topical cyclosporine and psoriasis
102. Topical cyclosporine in psoriasis
103. Cyclosporine A in the treatment of posterior uveitis
104. Treatment of intraocular inflammatory disease with cyclosporine A
105. Effectiveness of cyclosporine therapy for Behcet's disease
106. Cyclosporine in Behcet's disease (letter)
107. Short‐term cyclosporine A treatment of Behcet's disease
108. Double‐masked trial of cyclosporine versus colchicine and long‐term open study of cyclosporine in Behcet's disease
109. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome
110. Cyclosporine A in the treatment of severe Behcet's disease
111. Cyclosporine in Behcet's disease resistant to conventional therapy
112. Cyclosporine A is effective, but not safe, in the management of Behcet's disease
113. The use of cyclosporine in ocular inflammatory disorders
114. Cyclosporine therapy in Behcet's disease
115. Effective treatment of pyoderma gangrenosum with cyclosporine: a report of five cases
116. Pyoderma gangrenosum treated with cyclosporine A
117. Treatment of recalcitrant pyoderma gangrenosum with cyclosporine
118. Pyoderma gangrenosum: response to cyclosporine A
119. Cyclosporine therapy for pyoderma gangrenosum associated with sclerosing cholangitis and ulcerative colitis
120. Treatment of pyoderma gangrenosum with cyclosporine
121. Treatment of epidermolysis bullosa acquisita with cyclosporine (letter)
122. Clearing of epidermolysis bullosa acquisita with cyclosporine
123. Cyclosporine A in epidermolysis bullosa acquisita
124. Clearing of epidermolysis bullosa acquisita with cyclosporine
125. Treatment of severe lichen planus with cyclosporine
126. Cyclosporine A in the treatment of lichen planus
127. Effect of local application of cyclosporine on chronic erosive lichen planus of the oral cavity
128. Severe lichen planus clears with very low‐dose cyclosporine
129. Effect of topical cyclosporine rinse on oral lichen planus: a double‐blind analysis
130. Severe atopic eczema: response to oral cyclosporine A
131. Resolution of atopic dermatitis in a patient treated with cyclosporine
132. Cyclosporine therapy for severe atopic dermatitis
133. Double‐blind controlled, crossover study of cyclosporine in adults with severe refractory atopic dermatitis
134. Cyclosporine in atopic dermatitis
135. Can cyclosporine A induce permanent remission of atopic dermatitis
136. Guidelines for care of atopic dermatitis
137. Randomized double‐ blind placebo‐controlled trial of local cyclosporine in atopic dermatitis
138. Cyclosporine A‐induced hair growth in human renal allograft recipients and alopecia areata
139. Oral cyclosporine A for the treatment of alopecia areata: a clinical and immunohistochemical analysis
140. Topical cyclosporine in alopecia areata and nickel contact dermatitis
141. Placebo‐controlled trial of topical cyclosporine in severe alopecia areata
142. Topical cyclosporine in alopecia areata
143. Alopecia areata. A review of therapy, efficacy, safety, and mechanism
144. Cyclosporine and male‐pattern alopecia
145. Status of medical treatment of androgenetic alopecia
146. Effects of oral and topical cyclosporine in male pattern alopecia
147. Topical cyclosporine in male pattern alopecia
148. Actinic reticuloid: a clinical, photobiologic, histopathologic and follow‐up study of 16 patients
149. Development of cutaneous pseudolymphoma following cyclosporine therapy of actinic reticuloid
150. Persistent light reaction: successful treatment with cyclosporine A
151. Actinic reticuloid: response to cyclosporine
152. Successful treatment of musk ketone‐induced chronic actinic dermatitis with cyclosporine and PUVA
153. Treatment of nine cases of pemphigus vulgaris with cyclosporine
154. Treatment of pemphigus with cyclosporine
155. Pemphigus foliaceus and response to cyclosporine
156. Effects of cyclosporine on bullous pemphigoid and pemphigus
157. Cyclosporine A in der Behandlung von Pemphigus foliaceus and Pemphigus erythematosus
158. Bullous pemphigoid and response to cyclosporine
159. Cyclosporine treatment of steroid‐resistant interstitial pneumonitis associated with dermatomyositis/polymyositis
160. Cyclosporine for polymyositis
161. Cyclosporine for polymyositis
162. Cyclosporine in the treatment off intractable polymyositis
163. Cyclosporine for dermatomyositis
164. Cyclosporine treatment for intractable polymyositis
165. Cyclosporine therapy in chronic slowly progressive polymyositis‐preliminary report of clinical results in three patients
166. Cyclosporine for juvenile dermatomyositis
167. Cyclosporine for acute dermatomyositis
168. Cyclosporine in juvenile dermatomyositis
169. Cyclosporine A for the treatment of systemic lupus erythematosus
170. Possible beneficial effect of cyclosporine in some cases of severe systemic lupus erythematosus
171. Cyclosporine (CsA) and therapeutic plasma exchange in steroid‐resistant SLE
172. The effects of cyclosporine in patients with systemic lupus
173. Open therapeutic trial of cyclosporine in systemic lupus erythematosus. Preliminary results in 4 patients
174. Treatment of systemic lupus with cyclosporine A: a patient with a 1‐year‐follow‐up
175. The place of cyclosporine A in the treatment of connective tissue diseases
176. Cyclosporine in the treatment of lupus erythematosus
177. Combined cyclosporine‐ steroid treatment of systemic lupus erythematosus
178. Skin collagen from scleroderma patients before and after cyclosporine A treatment
179. Cyclosporine A in progressive systemic sclerosis
180. Cyclosporine treatment of scleroderma (PSS)
181. Cyclosporine in successful control of rapidly progressive scleroderma
182. Cyclosporine A in systemic sclerosis
183. Cyclosporine in the treatment of progressive systemic sclerosis
184. Cyclosporine therapeutic effects in rheumatic diseases
185. Improvement of ichthyosis by cyclosporine
186. Cyclosporine in lamellar ichthyosis
187. Cyclosporine A is selectively cytotoxic to human leukemic T cells in vitro
188. Treatment of cutaneous T cell lymphoma with cyclosporine A
189. Remission in skin infiltrate of a patient with mycosis fungoides treat ed with cyclosporine
190. Treatment of therapy‐resistant Sezary syndrome with cyclosporine A: suppression of pruritus, leukemic T cell action markers and tumor mass
191. Remission of Sezary's syndrome with cyclosporine A. Mild capillary leak syndrome as an unusual side effect
192. Cyclosporine A therapy for mycosis fungoides
193. Sezary syndrome: transformation to a high grade T‐cell lymphoma after treatment with cyclosporine A
194. Cyclosporine A (cyclosporine) in the treatment of cutaneous T cell lymphoma (mycosis fungoides)
195. Extracutaneous spreading with fatal outcome of mycosis fungoides in a patient treated with cyclosporine A: a word of caution
196. Sweet's syndrome responding to cyclosporine
197. A case of Sweet's syndrome and myelodysplasia: response to cyclosporine
198. Relapsing polychondritis‐treatment with cyclosporine A